164 related articles for article (PubMed ID: 15268896)
1. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
Sutherland MK; Geoghegan JC; Yu C; Winkler DG; Latham JA
Bone; 2004 Aug; 35(2):448-54. PubMed ID: 15268896
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
Sutherland MK; Geoghegan JC; Yu C; Turcott E; Skonier JE; Winkler DG; Latham JA
Bone; 2004 Oct; 35(4):828-35. PubMed ID: 15454089
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts.
Tardif G; Hum D; Pelletier JP; Boileau C; Ranger P; Martel-Pelletier J
Arthritis Rheum; 2004 Aug; 50(8):2521-30. PubMed ID: 15334466
[TBL] [Abstract][Full Text] [Related]
4. The role of noggin in human mesenchymal stem cell differentiation.
Rifas L
J Cell Biochem; 2007 Mar; 100(4):824-34. PubMed ID: 17133353
[TBL] [Abstract][Full Text] [Related]
5. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
6. Effects of TGF-beta2, BMP-4, and gremlin in the trabecular meshwork: implications for glaucoma.
Wordinger RJ; Fleenor DL; Hellberg PE; Pang IH; Tovar TO; Zode GS; Fuller JA; Clark AF
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1191-200. PubMed ID: 17325163
[TBL] [Abstract][Full Text] [Related]
7. Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells.
Delgado-Calle J; Arozamena J; Pérez-López J; Bolado-Carrancio A; Sañudo C; Agudo G; de la Vega R; Alonso MA; Rodríguez-Rey JC; Riancho JA
Mol Cell Endocrinol; 2013 Apr; 369(1-2):27-34. PubMed ID: 23415712
[TBL] [Abstract][Full Text] [Related]
8. Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential.
Fakhry A; Ratisoontorn C; Vedhachalam C; Salhab I; Koyama E; Leboy P; Pacifici M; Kirschner RE; Nah HD
Bone; 2005 Feb; 36(2):254-66. PubMed ID: 15780951
[TBL] [Abstract][Full Text] [Related]
9. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
10. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone enhances bone morphogenetic protein activity by increasing intracellular 3', 5'-cyclic adenosine monophosphate accumulation in osteoblastic MC3T3-E1 cells.
Nakao Y; Koike T; Ohta Y; Manaka T; Imai Y; Takaoka K
Bone; 2009 May; 44(5):872-7. PubMed ID: 19442611
[TBL] [Abstract][Full Text] [Related]
13. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts.
Pereira RC; Economides AN; Canalis E
Endocrinology; 2000 Dec; 141(12):4558-63. PubMed ID: 11108268
[TBL] [Abstract][Full Text] [Related]
15. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
17. Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells.
Grundberg E; Brändström H; Lam KC; Gurd S; Ge B; Harmsen E; Kindmark A; Ljunggren O; Mallmin H; Nilsson O; Pastinen T
Physiol Genomics; 2008 May; 33(3):301-11. PubMed ID: 18334548
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of bone morphogenetic protein-2 expression and bone formation by coumarin derivatives via p38 and ERK-dependent pathway in osteoblasts.
Tang CH; Yang RS; Chien MY; Chen CC; Fu WM
Eur J Pharmacol; 2008 Jan; 579(1-3):40-9. PubMed ID: 17980360
[TBL] [Abstract][Full Text] [Related]
19. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts.
Shin SS; Liu C; Chang EY; Carlson CS; Di Cesare PE
J Hand Surg Am; 2004 Sep; 29(5):809-14. PubMed ID: 15465229
[TBL] [Abstract][Full Text] [Related]
20. Bone morphogenetic protein activities are enhanced by 3',5'-cyclic adenosine monophosphate through suppression of Smad6 expression in osteoprogenitor cells.
Sugama R; Koike T; Imai Y; Nomura-Furuwatari C; Takaoka K
Bone; 2006 Feb; 38(2):206-14. PubMed ID: 16203197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
